A patient tumor with MEN1, BRCA2, PTEN, and SETD2 mutations was passaged in PDX models to create everolimus resistant tumors, followed by treatment with sapaniseritinb, a potent dual mTORC1/2 inhibitor, to overcome resistance. This evidence concerns the gene MEN1 and neoplasm.